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Acute respiratory distress syndrome (ARDS) is defined as the acute onset of noncardiogenic edema and subsequent gas-exchange
impairment due to a severe inflammatory process. Recent report on the prognostic value of eicosanoids in patients with ARDS
suggests that modulating the inflammatory response through the use of polyunsaturated fatty acids may be a useful strategy for
ARDS treatment.The use of enteral diets enriched with eicosapentaenoic acid (EPA) and gamma-linolenic acid (GLA) has reported
promising results, showing an improvement in respiratory variables and haemodynamics. However, the interpretation of the studies
is limited by their heterogeneity andmethodology and the effect of𝜔-3 fatty acid-enriched lipid emulsion or enteral diets on patients
with ARDS remains unclear. Therefore, the routine use of 𝜔-3 fatty acid-enriched nutrition cannot be recommended and further
large, homogeneous, and high-quality clinical trials need to be conducted to clarify the effectiveness of 𝜔-3 polyunsaturated fatty
acids.
1. Introduction
Acute respiratory distress syndrome (ARDS), defined as the
acute onset of noncardiogenic edema and subsequent gas-
exchange impairment due to a severe inflammatory process,
affects 78.9 cases per 100,000 person-years in the US and is
one of themain reasons for ICU admission [1]. Despite recent
advances in overall support, it is still associated with high
rates of mortality [1, 2], reduced quality of life [3, 4], and
increased healthcare costs [5].
Adjunctive nutritional support is a strategy that is cur-
rently receiving growing attention in the management of
critically ill patients. In particular, it has been suggested
that supplementation with 𝜔-3 fatty acids may modulate
the inflammatory response in ARDS, although the evidence
compiled so far is limited.The aim of this review is, therefore,
to discuss recent evidence regarding the role of 𝜔-3 fatty
acids-enriched diets in patients with ARDS.
2. Acute Respiratory Distress Syndrome
According to the latest review by a panel of experts from the
European Society of Intensive Care Medicine, the Society of
Critical Care Medicine, and the American Thoracic Society
[6] (Table 1), ARDS is defined as the onset of acute respiratory
failure (PaO2/FIO2 < 300mmHg, with a minimum level
of positive end expiratory pressure) with bilateral opacities
within a week of a known clinical insult, not fully explained
by cardiac failure or fluid overload (using objective assess-
ment tools such as echocardiography to exclude hydrostatic
oedema). The clinical insult may be either intra or extrapul-
monary. The most frequent causes of ARDS are pneumonia
and extrapulmonary severe sepsis [7–9].
Regardless of the primary insult, the lung response
has classically been considered as a stereotypical process,
characterized by the activation of inflammatory, coagulation,
and fibrinolytic systems that lead to lung inflammation
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Table 1: Berlin definition of ARDS.
Timing Within one week of a known clinical insult or new or worsening respiratory symptoms.
Chest imaging Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules.
Origin of oedema Respiratory failure not fully explained by cardiac failure or fluid overload. Need for objectiveassessment (e.g., echocardiography) to exclude hydrostatic oedema if no risk factors are present.
Oxygenation
Mild 200mmHg < PaO2/FIO2 ≤ 300mmHg with PEEP or CPAP ≥ 5 cmH2O
Moderate 100mmHg < PaO2/FIO2 ≤ 200mmHg with PEEP ≥ 5 cmH2O
Severe PaO2/FIO2 ≤ 100mmHg with PEEP ≥ 5 cmH2O
PaO2: partial pressure of arterial oxygen; FIO2: fraction of inspired oxygen; PEEP: positive end expiratory pressure; CPAP: continuous positive airway pressure.
and the subsequent epithelial-endothelial barrier injury [10].
Inflammatory mediators may also cause loss of the vascular
tone leading to vasoconstriction and creating parched areas
of lung destruction [11].
The inflammatory cascade involves large numbers of
inflammatory cells andmediators, many of which are directly
produced in the lung. It is accompanied by a change in
bronchoalveolar lavage (BAL) cellularity, due to neutrophils
migration [12]. Neutrophil migration and activation may,
then, be the main trigger of lung injury. They produce toxic
molecules, chemokines (e.g., IL-1, IL-8, NTFa, L-selectin, and
CXCL-CXCR complex), adhesion molecules (e.g., ICAM,
PECAM) [13, 14], and procoagulant substances [15]. It has
been proved that during lung injury there are proinflamma-
tory as well as anti-inflammatory mediators in BAL fluid and
serum, suggesting that it may be the balance between them
that regulates lung damage and repair [13].
ARDS is, therefore, a heterogeneous syndrome with no
specific treatment. In addition to addressing the primary
insult and providing support measures, many therapeutic
options have been tested in order to improve the clinical
outcome in these patients. Until now, protective mechan-
ical ventilation [16] and prone-positioning in the more
severe patients [17] are the only strategies that have clearly
demonstrated their usefulness for ARDSmanagement. Other
treatments such as neuromuscular blockage, vasodilators,
anti-inflammatory drugs, extracorporeal support, or high
frequency oscillating ventilation have obtained inconclusive
results [18–21]. The effect of protective ventilation strategies
on mortality seems to be related to the decrease in cytokine
response induced by mechanical ventilation, minimizing the
degree of ventilation-induced lung injury and subsequent
biotrauma [22]. The possibilities of nutritional support have
also been investigated in depth: recent studies suggest that
lipid emulsions and enteral 𝜔-3 fatty acid supplementation
may have an effect on the inflammatory process, not only in
ARDS but in other critical conditions as well.
3. 𝜔-3 Polyunsaturated Fatty Acids
Fatty acids are crucial to human life: they are a main source
of energy, they have structural functions as part of the
cell membrane, and they participate in cell signalling and
response [23]. Essential polyunsaturated fatty acids (PUFA)
are linoleic acid (LA, PUFA 𝜔-6 series) and linolenic acid
(LNA, PUFA 𝜔-3 series), which must be obtained through
the diet. Linoleic acid is the endogenous precursor of
arachidonic acid (AA), which joins the phospholipids in the
cell membrane, while LNA is related to eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA). However,
direct ingestion of these acids (from fish, shellfish, and
algae) seems to be a more efficient source. Oxygenation
and lipoxygenase enzymes transform AA into eicosanoids
such as prostaglandins, thromboxanes, and leukotrienes,
which have a high biological activity and play a major role
in the inflammatory response (Figure 1). In contrast, LNA
derivatives are much less active. As they both use the same
metabolic routes, 𝜔-3 fatty acids compete with AA for the
conversion to lipid mediators, balancing the negative effects
of 𝜔-6 fatty acids [24] (Figure 2).
The prognostic value of eicosanoids in patients with
ARDS was studied by Masclans et al. [25] in a prospective
study including 21 patients. Plasma levels of thrombox-
ane B2 (TXB2), prostaglandin F1-alpha (PGF1-alpha), and
leukotriene B4 (LTB4) were measured both in peripheral
and pulmonary arterial samples and in venous samples
within 48 h of ARDS onset. ARDS patients showed signif-
icantly higher levels of eicosanoids than a reference group
of healthy subjects. However, only LTB4 correlated with
lung injury score (in peripheral and pulmonary blood).
Nonsurvivors presented a lower systemic-pulmonary arterial
gradient of eicosanoid levels than survivors. A more recent
study assessed the value of LTB4-levels as clinical markers for
predicting pulmonary complications such as ARDS, respira-
tory failure, pulmonary embolism, or pneumonia in multiply
traumatized patients [26]. The results showed that LTB4
levels were significantly higher in patients who presented
pulmonary complications, suggesting that this mediator may
play a role in their pathogenesis.
The possible prognostic value of leukotriene B(4) in
ARDS was again reported by Masclans et al. in a prospective
study of 16 ARDS patients admitted to the ICU [27]. These
authors found higher plasma concentrations of thromboxane
B(2), 6-keto-prostaglandin F(1alpha), and leukotriene B(4)
compared to the general population, but only leukotriene
B(4) was higher in arterial plasma than in mixed venous
plasma. Baseline PaO2/FIO2 correlated with levels of arterial
thromboxane B(2) and arterial leukotriene B(4) and the
transpulmonary gradient of leukotriene B(4). A correlation
between the transpulmonary gradient of leukotriene B(4)
























Figure 1: Eicosanoid metabolic pathways.
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Figure 2: Effects of 𝜔-3 polyunsaturated fatty acids in ARDS.
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and the lung injury score was also found. Moreover, among
nonsurvivors a substantial positive gradient of leukotriene
B(4) was detected. Thus, leukotriene B(4) may correlate with
lung injury severity and outcome in patients with ARDS.
These results suggest that modulating the inflammatory
response through the use of PUFA may be a useful strategy
for ARDS treatment.
Classically, the nutrition of critically ill patients was
particularly rich in long-chain triglycerides such as linoleic
acid. LA may have a harmful effect on the immune and
pulmonary function due to its proinflammatory properties,
as it is the precursor ofAAand eicosanoids. For this reason, in
recent years several strategies have been developed in order to
minimize these effects: for example, emulsionswith amixture
of long-chain and medium-chain fatty acids, enriched with
olive oil or with 𝜔-3 fatty acids [28]. To date, however, the
results regarding the administration of mixed emulsions are
inconclusive and the use of olive oil in patients with ARDS
has not been studied in depth.
As for the most recent 𝜔-3 fatty acids enriched formulas,
they may have a beneficial effect on ARDS as they compete
with 𝜔-6 PUFA and minimize the synthesis of proinflam-
matory eicosanoids. They contribute to the modulation of
nuclear receptor activation (i.e., NF-kappaB suppression),
the suppression of arachidonic acid-cyclooxygenase-derived
eicosanoids (primarily prostaglandin E(2)) and the alteration
of the plasma membrane microorganization related to the
function of Toll-like receptors (TLRs), and immune cell
recruitment [29].
4. Recent Findings in the Use of 𝜔-3 PUFA in
Patients with ARDS
4.1. Experimental Studies. Several experimental studies have
reported the effect of 𝜔-3 PUFA in animal models. In a
murine model, Mancuso et al. [30] compared the effects of
fish oil, fish and borage oil, and corn oil. Fish oil and fish
and borage oil seemed to improve endotoxin-induced acute
lung injury by suppressing the levels of proinflammatory
eicosanoids in bronchoalveolar lavage fluid and reducing
neutrophil accumulation in lungs. Palombo et al. [31] studied
the effect of short-term enteral feeding with eicosapentaenoic
acid-enriched or eicosapentaenoic with gamma-linolenic
acid-enriched diets in rats. These diets seemed to modulate
the fatty acid composition of alveolar macrophage phos-
pholipids, minimizing the formation of less inflammatory
eicosanoids.
4.2. Human Studies. Research on patients with ARDS dates
back to some 15 years (Table 2). Initially, the focus wasmainly
on the use of amixture of long-chain andmedium-chain fatty
acids.
Masclans et al. [32] conducted a randomized trial to
evaluate the effect on gas exchange and pulmonary haemo-
dynamics of two different intravenous fat emulsions in 21
patients with ARDS. Patients were randomized to receive
a long-chain triglyceride-enriched emulsion (20% LCT),
a medium-chain triglyceride/long-chain triglyceride emul-
sion (20% MCT/LCT: 50/50), or placebo, at a slow rate
(2mg/Kg/min). Increases in cardiac output, oxygen con-
sumption, and oxygen delivery were found during LCT infu-
sion. However, no differences in pulmonary haemodynamics
and arterial oxygen tension were detected, suggesting that,
at a slow rate, the beneficial effect on cardiac output of LCT
infusion offsets the detrimental effect of increased oxygen
consumption. No changes were observed in the MCT/LCT
group. In this case, the effect of 𝜔-3 was not analysed.
Suchner et al. [33] studied the effect of fat emulsions
on pulmonary haemodynamics and gas exchange in patients
with ARDS or sepsis. In a prospective crossover study, eight
patients with ARDS and 10 patients with sepsis were random-
ized to receive intravenous fat emulsions (LCT/MCT) over
6 h (rapid fat infusion) or 24 h (slow fat infusion) along with
a routine parenteral nutrition regimen. In the ARDS group,
patients who received rapid fat infusion presented increased
prostaglandin I2/thromboxane A2 (P/T) ratios, higher pul-
monary shunt, and a decrease in oxygenation. As for the
haemodynamics, patients presented decreased pulmonary
and systemic vascular resistances while their cardiac indices
increased. Increasing plasma concentrations of TxA2 were
associatedwith improved respiratory performance. All values
returned to baseline after 12 h. It was therefore suggested
that fat emulsion-derived vasodilatory PGI2 may increase
pulmonary shunt and affect gas exchange by increasing
pulmonary blood flow and decreasing pulmonary vascular
tone. The conclusion is that the speed of infusion also plays
an important role.
In contrast, patients with severe sepsis showed reduced
pulmonary shunt and increased oxygenation index, while the
P/T ratio and haemodynamics remained unchanged.
Faucher et al. [34] conducted a crossover study including
18 patients withARDSwhowere randomized to receive either
a 6 h infusion of a fat emulsion containing LCT or an infusion
of 50% LCT/50% MCT. LCT emulsion showed no effect
on oxygenation, whereas MCT/LCT emulsion significantly
improved PaO2/FIO2 by 16% 1 h after initiating the infusion
and cardiac output as well. However, the changes were
transitory and oxygenation and haemodynamic parameters
were similar to baseline at the end of the infusion.
The results regarding the administration of mixed emul-
sions (LCT/MCT) were not conclusive, probably because
the administration of LCT decreases but the ratio 𝜔-6/𝜔-3
remains unchanged. Subsequent research focused on the use
of 𝜔-3 enriched nutrition and obtained promising results. A
meta-analysis of three trials including 296 patients published
by Pontes-Arruda et al. [35] suggested that enteral supple-
mentation with 𝜔-3 fatty acids and gamma-linolenic acid
(GLA) could significantly reduce the risk of mortality, the
duration of mechanical ventilation, and ICU stay in patients
with ARDS.
In 1999, Gadek et al. [36] studied the effect of enteral
feeding with eicosapentaenoic acid, gamma-linolenic acid,
and antioxidants in patients with ARDS. One hundred and
forty-six patients with ARDS were randomized to receive
either eicosapentaenoic acid (EPA) + gamma-linolenic acid
(GLA) or isonitrogenous, isocaloric standard diet for 4–7
days. Significant improvements in oxygenation were found in
patients fed with EPA + GLA compared with controls. These
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Table 2: Omega-3 polyunsaturated fatty acids in ARDS.
Author/year Design 𝑁 Intervention Main outcomes




↑CO, O2 consumption and delivery
= Pulmonary haemodynamics and arterial O2
tension
Suchner et al., 2001 [33] RCT(crossover) 18
Rapid (6 hr) versus slow
(24 hr) fat emulsion,
LCT/MCT
Rapid: ↑P/T, pulmonary shunt and CO; ↓PVR,
SVR, and PaO2/FIO2
Faucher et al., 2003 [34] RCT(crossover) 18
LCT/MCT (versus LCT),
6 hr Transitory ↑PaO2/FIO2
Gadek et al., 1999 [36] RCT,multicentre 146 EPA + GLA, 4–7 days
↑PaO2/FIO2
↓Days of MV and UCI LOS









↓LTB4, TXB2, 6-keto-PG during infusion
Singer et al., 2006 [39] RCT, single-centre 100




Pontes-Arruda et al., 2011 [40] RCT,multicentre 115
EPA + GLA (versus
standard),
7 days
↓Severe sepsis and SS
↓Cardiac and respiratory failure
↓Days of MV and UCI LOS
= 28-day mortality




↓MV-free days, ICU-free days, nonpulmonary
organ failure-free days
Stopped for futility
Stapleton et al., 2011 [42] RCT,multicentre 90




= IL-8 in BALF, organ failure score, MV-free
days, ICU-free days, and 60-day mortality
Grau-Carmona et al., 2011 [43] RCT,multicentre 132
EPA + GLA (versus
standard) = Oxygenation and organ failures
Elamin et al., 2012 [44] RCT,multicentre 17
EPA + GLA (versus
standard),
7 days
↓LIS, ICU LOS, 28-day multiorgan dysfunction
score
= Mortality
RCT: randomized controlled trial; LCT: long-chain triglycerides; MCT: medium-chain triglycerides; CO: cardiac output; EPA: eicosapentaenoic acid; GLA:
gamma-linolenic acid; PaO2/FIO2: partial pressure of arterial oxygen/fraction of inspired oxygen; MV: mechanical ventilation; ICU LOS: intensive care unit
length of stay; P/T: prostaglandin I2/thromboxane A2 ratio; PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; LTB4: leukotriene B4;
TXB2: thromboxane B2; 6-keto-PG: 6-keto-prostaglandin; IL-8: interleukin 8; BALF: bronchoalveolar lavage fluid; LIS: lung injury score.
patients also required significantly fewer days of mechanical
ventilation and a shorter length of stay in the intensive care
unit.
Sabater et al. studied the effect of 𝜔-3 fatty acid-enriched
lipid emulsion on haemodynamics and gas exchange in
patients with ARDS. In a randomized, parallel group study
[37], 16 patients were included and randomized to receive
the control emulsion (100% LCT) or the study emulsion
(50% MCT, 40% LCT, 10% 𝜔-3) for 12 h. No differences
in gas exchange or haemodynamics were found, except for
pulmonary capillary pressure, which was lower in the group
with the study emulsion; these results suggested that both
emulsions were clinically safe.
In those patients, significant short-term changes in
eicosanoid synthesis have been identified [38]. Levels of
LTB4, TXB2, and 6-keto-prostaglandin F1-alpha in arterial
and mixed venous blood samples increased during infusion
in the LCT group and returned to baseline after discontinu-
ation. In the study group, mediator levels decreased during
infusion and then behaved erratically. It has been suggested
that leukotrienes, particularly LTB4, play a crucial role in lung
injury, and their activity may help to modulate the immune
response.
Singer et al. [39] reported a beneficial effect of an enteral
diet enriched with eicosapentaenoic acid (EPA) and gamma-
linolenic acid (GLA) in oxygenation and lung dynamics in 95
patients with ARDS. Those authors found significant differ-
ences in PaO2/FIO2, but this improvement was lost by day 14.
Improvements in static compliance and length of mechanical
ventilation were also observed, although these differences
were not clinically relevant. No changes in mortality were
reported.
However, the characteristics of the control diet must also
be taken into consideration. In some of these studies (i.e.,
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Gadek et al., Singer et al.) the control group received a diet
with a high content of fatty acids, particularly linoleic acid,
which may have had a deleterious effect. What is more,
in addition to 𝜔-3 FA, formulas also included vitamins,
antioxidants, and other elements that could have an effect
on the inflammatory reaction, making it difficult to establish
the real benefit of each single component on its own. These
studies also have some other limitations: for instance, no
information was provided on other therapeutic strategies
such asmechanical ventilation or fluid administration, which
we now know that they have a major role in the management
of ARDS. The design of later studies attempted to overcome
these limitations.
Studying the effect of enteral nutrition with EPA/GLA
and antioxidants in patients in early stages of sepsis with-
out associated organ dysfunction, Pontes-Arruda et al. [40]
showed a more frequent progression to severe sepsis and
septic shock in the control group, particularly due to devel-
opment of cardiovascular and respiratory failure. Enteral
nutrition with EPA/GLA may then play a beneficial role by
slowing the progression of severe forms of sepsis. The study
group showed shorter length of stay, lower incidence, and
shorter duration ofmechanical ventilation, but no differences
were found in 28-day all-cause mortality.
The OMEGA study was a randomized multicentre trial
which lasted one year and included 272 patients with ARDS
[41]. Patients received a twice daily supplementation of 𝜔-3
fatty acids, GLA, and antioxidants or an isocaloric control
(enteral nutrition was delivered separately). Surprisingly, the
study had to be stopped for futility. The enteral diet was
reported to be less well tolerated than in previous studies,
with a higher incidence of diarrhoea. Patients in the 𝜔-3
group had fewer ventilator-free days, ICU-free days, and
nonpulmonary organ failure-free days.The authors therefore
concluded that enteral supplementation with 𝜔-3 fatty acids,
GLA, and antioxidants did not improve outcomes and might
be harmful. In spite of its early termination this study
presented certain methodological advantages over previous
trials: mechanical ventilation and fluid administration were
controlled in both groups, and the control group received a
less proinflammatory diet, as well as a high intake of proteins,
which may have had a beneficial effect.
In a phase II multicentre, randomized placebo-controlled
trial, Stapleton et al. [42] reported that mechanically venti-
lated patients with acute lung injury receiving enteral fish
oil (EPA and DHA) had increased levels of EPA in BALF
with no differences in other biomarkers (e.g., IL-8), organ
failure score, ventilator-free days, ICU-free days, or 60-
day mortality. Those authors suggested that the positive
results of previous studies may have been related to the
deleterious effect of control diets. Therefore, the beneficial
effect could not be attributed to 𝜔-3 PUFA but possibly to
other components of the diet or to their combined action.
Grau-Carmona et al. [43] conducted a randomized, open-
label study in 11 Spanish intensive care units, including 132
patients with sepsis and established ARDS [31]. Patients
were randomized to receive an enteral diet enriched with
eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA),
and antioxidants or a control diet. No differences in gas
exchange or novel organ failures were observed between the
two groups.
In contrast, another multicentre randomized trial con-
ducted by Elamin et al. [44] showed an association between
an EPA- and GLA-supplemented diet and improvement in
gas exchange. Patients in the study group presented reduc-
tions in lung injury score, ICU length of stay, and 28-day
multiorgan dysfunction score. No differences in survival were
detected.However, the sample comprised only 17 patients and
so the results should be considered with caution.
In view of the contradictory nature of these results, a
systematic review andmeta-analysis were recently performed
to investigate the beneficial or harmful effect of enteral
supplementation of 𝜔-3 fatty acids in patients with ARDS
[45]. The meta-analysis of seven trials including 955 patients
showed no significant decrease in all-cause 28-day mortality
or ICU-free days with the use of enteral 𝜔-3 fatty acids.
Obviously, the analysis had its limitations: most of the trials
were performed in small samples and used different control
formulas. Nevertheless, it was significant that the 𝜔-3 fatty
acid-enriched enteral diet was generally well tolerated, with
no reports of adverse events.
Nearly all studies considering the effect of 𝜔-3 have been
conducted using the enteral route. It should be borne inmind
that patients with ARDS may present digestive intolerance,
due to deep sedation, neuromuscular blockage, ormechanical
ventilation, whichmay limit the use of enteral nutrition. Little
is known about the parenteral route in this particular group
of patients. This route is worth exploring, as it offers several
potential advantages such as the rapid incorporation of the FA
into the cell membrane and the possibility of administering
higher doses of these lipids.
5. Conclusion
The effect of 𝜔-3 fatty acid-enriched lipid emulsion or enteral
diets on respiratory and cardiovascular variables in patients
with ARDS remains unclear.These diets appear to interfere in
eicosanoid synthesis, modulating the inflammation response
in patients with lung injury. Although enteral 𝜔-3 PUFA-
enriched diets have a robust physiopathological basis and
some promising results were initially reported in experimen-
tal and human studies, recent research has cast doubt on
their real impact on patients with ARDS. In fact, scientific
societies such as the Canadian Society for Clinical Nutrition
are currently lowering the level of evidence of these strategies.
The interpretation of the studies is limited by several
factors, principally their heterogeneity andmethodology. For
example,most of the trials are single-centre studieswith small
sample sizes and include heterogeneous groups of patients
with different aetiologies and degrees of severity. Many of
them lack information concerning clinicalmanagement, such
as mechanical ventilation strategies, and different formulas,
route of administration, rate of infusion, and treatment
duration have been used. The ideal doses, route, and time
of administration are still to be established. In general, the
effects on oxygenation are transitory and no clear differences
in important clinical outcomes such as mortality have been
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reported. However, the use of lipid formulas seems to be safe
and well tolerated.
Based on this evidence, the routine use of 𝜔-3 fatty acid-
enriched nutrition cannot be recommended. Further large,
homogeneous, and high-quality clinical trials need to be
conducted to conclusively determine its effectiveness.
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